

****Published July 2018****

MarketVIEW: Chikungunya virus vaccines (CAT: VAMV005)

Product Name	:	MarketVIEW: Chikungunya virus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (~120 slides.pdf) + MS-Excel forecast model(s) (.xls)
Therapeutic Area	:	Chikungunya virus vaccines
Publication date	:	July 2018
Catalogue No	:	VAMV005

Background

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia. In some cases, the virus can cause recurrent disease (post-CHIK rheumatic disorder), neurological complications and severe neonatal disease (encephalopathy). CHIK is not generally considered a life-threatening disease, with an estimated case-fatality rate of 0.1%. However, concerns are increasing. In 2016, the Brazilian Ministry of Health recognised more than 200 deaths related to CHIK infection.¹

Although CHIK is endemic in Africa/Southeast Asia, recently outbreaks have occurred in previously CHIK free countries, including China, Papua New Guinea, Laos, New Caledonia and Bhutan. In the two years between 2014-2016, a large increase in CHIK transmission occurred in the Americas. The latest CDC appraisal released May 29th, 2018 indicated even more countries have been affected in Africa, Middle East and Europe (Spain).

A number of potential CHIK vaccine candidates (based on various approaches) are now in the clinical stages of development including those from **PaxVax, Inc**, **Themis Bio GmbH**, **Valneva Austria GmbH**. The **PaxVax, Inc** vaccine candidate received fast-track designation by the FDA in May 2018. A CHIK vaccine could be used in vulnerable populations in both endemic public/private markets and possibly in Western travellers (profile dependent).

This **MarketVIEW** product is a comprehensive commercial evaluation containing an Executive Presentation (~110 slides) and MS Excel Workbook (.xls) examining the potential (value/volume) of a prophylactic Chikungunya vaccine to 2035. The prospects of the vaccine in "First time" and "Repeat" Western travellers (Visiting Friends/Family and Business + Other)², endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided.

¹A Brazil case study is provided in this study

² **FROM WESTERN COUNTRIES** = FROM US, CANADA, UK, GERMANY, FRANCE, ITALY, SPAIN, FINLAND, NORWAY, SWEDEN, AUSTRALIA, SOUTH KOREA AND JAPAN,

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Chikungunya virus vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral and flavivirus based-pathogens has also been utilised.

PRODUCT CONTENTS:

Published July 2018 (CAT No: VAMV005)

****This product is a [summary presentation \(.pdf\)](#), [a forecast model \(.xls\)](#)

Contents – Summary presentation (.pdf)³

Contents

Author's notes

Executive summary

[SECTION 1] Chikungunya virus vaccines: key model outputs

[SECTION 2] Chikungunya virus vaccines: commercial model assumptions outputs

[SECTION 3] Chikungunya virus: disease background and epidemiology

[SECTION 4] Chikungunya virus: disease trends and future dynamics

[SECTION 5] Chikungunya virus: R&D pipeline and competitor activity

[SECTION 6] Chikungunya virus vaccines: Overview of forecast methodology/caveats & limitations

References/bibliography

About **VacZine Analytics**

Disclaimer



SNAPSHOT

PAGES: ~120 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Worksheets = >90 interconnected

³ Full contents i.e. title per slide is available upon request

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8,995.00**/ GBP **£6810.00**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 927049

E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and “the spiral logo” are UK Registered Trademarks, 2009

